| 000 | 01924 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250514051420.0 | ||
| 264 | 0 | _c20030520 | |
| 008 | 200305s 0 0 eng d | ||
| 022 | _a0960-894X | ||
| 024 | 7 |
_a10.1016/s0960-894x(02)00789-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSlater, Martin J | |
| 245 | 0 | 0 |
_aDesign and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease. _h[electronic resource] |
| 260 |
_bBioorganic & medicinal chemistry letters _cDec 2002 |
||
| 300 |
_a3359-62 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAmino Acid Sequence |
| 650 | 0 | 4 |
_aCarrier Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 |
_aHepacivirus _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInhibitory Concentration 50 |
| 650 | 0 | 4 | _aIntracellular Signaling Peptides and Proteins |
| 650 | 0 | 4 |
_aLactams _xchemical synthesis |
| 650 | 0 | 4 | _aMicrobial Sensitivity Tests |
| 650 | 0 | 4 |
_aPyrrolidines _xchemical synthesis |
| 650 | 0 | 4 |
_aSerine Proteinase Inhibitors _xchemical synthesis |
| 650 | 0 | 4 | _aStereoisomerism |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 650 | 0 | 4 |
_aViral Nonstructural Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aViral Proteins _xantagonists & inhibitors |
| 700 | 1 | _aAndrews, David M | |
| 700 | 1 | _aBaker, Graham | |
| 700 | 1 | _aBethell, Susanne S | |
| 700 | 1 | _aCarey, Seb | |
| 700 | 1 | _aChaignot, Helene | |
| 700 | 1 | _aClarke, Berwyn | |
| 700 | 1 | _aCoomber, Barry | |
| 700 | 1 | _aEllis, Malcolm | |
| 700 | 1 | _aGood, Andrew | |
| 700 | 1 | _aGray, Norman | |
| 700 | 1 | _aHardy, George | |
| 700 | 1 | _aJones, Paul | |
| 700 | 1 | _aMills, Gail | |
| 700 | 1 | _aRobinson, Ed | |
| 773 | 0 |
_tBioorganic & medicinal chemistry letters _gvol. 12 _gno. 23 _gp. 3359-62 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0960-894x(02)00789-8 _zAvailable from publisher's website |
| 999 |
_c12227024 _d12227024 |
||